New medicine to prevent or lessen painful mouth sores from radiation
Preclinical assessment of a novel compound for treating radiation-induced oral mucositis
This project develops a potential drug to prevent or shorten painful mouth sores that happen after radiation therapy for head and neck cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sinopia Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11349200 on NIH RePORTER |
What this research studies
Researchers are testing a new compound in the lab and in preclinical models to see if it can prevent or heal the inflammation and ulcers that cause oral mucositis after radiation. The project also sponsors double-blind interviews with head and neck cancer specialists and mucositis experts to gather clinical insight. Market research and secondary analyses will define how many patients might benefit, pricing expectations, and the best clinical-development path. Those findings will guide whether and how the company moves the drug into human clinical trials.
Who could benefit from this research
Good fit: People receiving radiation to the head or neck who are at risk of developing radiation-induced oral mucositis would be the likely candidates for future clinical trials.
Not a fit: People not receiving head/neck radiation or whose mouth sores come from other causes are unlikely to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to a treatment that reduces the severity and duration of radiation-related mouth sores, easing pain and improving patients' ability to eat, speak, and complete cancer therapy.
How similar studies have performed: Some drugs have shown benefit for mucositis in transplant settings, but there are currently no widely accepted FDA-approved treatments for radiation-induced oral mucositis in solid tumors, so this approach remains relatively novel and unproven in humans.
Where this research is happening
San Diego, United States
- Sinopia Biosciences, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Lloyd, Colton Joseph — Sinopia Biosciences, INC.
- Study coordinator: Lloyd, Colton Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.